{"name":"Penumbra","slug":"penumbra","ticker":"PEN","exchange":"NYSE","domain":"penumbrainc.com","description":"The umbra, penumbra and antumbra are three distinct parts of a shadow, created by any light source after impinging on an opaque object of lesser size. In cases of equal or smaller impinging objects, only an umbra and penumbra are generated. Assuming no diffraction, for a collimated beam of light, only the umbra is cast.","hq":"Alameda, CA","founded":0,"employees":"4700","ceo":"Adam Elsesser","sector":"Medical Devices / Neurovascular","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":322.2,"stockChange":-0.39,"stockChangePercent":-0.12,"marketCap":"$12.7B","metrics":{"revenue":1454283008,"revenueGrowth":15.6,"grossMargin":67.4,"rdSpend":36165000,"netIncome":177687000,"cash":615660032,"dividendYield":0,"peRatio":74.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Penumbra Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Penumbra reported fourth quarter and full year 2023 financial results, with revenue of $444.8 million and $1.7 billion, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Penumbra Announces Agreement to Acquire Cerenovus","summary":"Penumbra announced an agreement to acquire Cerenovus, a neurovascular company, expanding its portfolio of neurovascular products.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Penumbra Receives FDA Clearance for Penumbra System","summary":"Penumbra received FDA clearance for its Penumbra System, a mechanical thrombectomy device for stroke treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPWFpoYW1fa3BkN3JNaFJXTnVaOFVSQld0cENscUh5LVJGeUIzSjY0MGFSYjNlbU1GVDU5TGNvMS1mTkxLN3FPaGloS0Ffbm9GRk1JbHNzNEpJWFZwQU9Va1BFZUNKcXBKVXdQT0VVYlVhc3IyR1k4SzlENnlKd2tYUlZGTnlscjlxaWN3MkZTakd4NThSQ3g4cXhzbW42bzYybV94Q3ZRNDk1V3hTcFZQOGJ2WmdZYWlKSGNnMjdybmZFWkJOS3FhSE1vOTBEUnUzYXhUZVBucTMtRW1yeWVRWElISnotNTdnWEJwMlZlUnBmZ0hTLWdzcVFLUld4andrVS1vX29VUXpGZkFDd3pOUC1NN2V4THh6RkxUWHBYbFpaeDZZaVdBeVB6VVVvRXBPZF9pVFZjVmdqSVk?oc=5","date":"2026-04-01","type":"pipeline","source":"Business Wire","summary":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA - Business Wire","headline":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE55NVRSVjlJVlFBYVJQUGdlZV81aG9na3VzeFF0VmNNTFE3bzIxcWtMeWxJSnJDWnZkOWxtT0hXZUlxRHdhLXVCU3JicnEzRnMzQXpaSmFjZnpmbHhyLU9mOE1pVkNRZlExYUx1X2Q3eGUzQWV4QWVUQ1VVM1BZQXM?oc=5","date":"2026-02-25","type":"earnings","source":"Finviz","summary":"Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025 - Finviz","headline":"Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSzdlVkpFeGptTlVsTGJ0TGRUeDdKVC03WjE2TmFZc3dyZGhtb1lkRFpEYTBpbXJUREV4YW4zV2RqUE9EYUdvU3lVYVpIa1p3V2VHcW51eXV6Mnk0dW9RWi1ORmhKVlU1WkRzYW5XUDA0eGpHWG1zLTlrQjZTUk5wTzdDQWdlRHoyU1FyVlJ3VW8xNjVZ?oc=5","date":"2026-02-24","type":"deal","source":"The Business Journals","summary":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree - The Business Journals","headline":"Boston Scientific adds Starbucks CFO, Takeda CEO to board amid $14.5B buying spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSnNrbXExVmI0c0I4VjgxdVkzVlhoM3doTnhpTEtrQ2QxMFVrVlAzeVprNVJSYkhwbHVjaVQtZ0xZanJmTXloSEQ0OXFNbXlEMm54aHcyeUhyNU1CWXJYSVdJWWc3WktKM2l5TFpIdFYzYXp0UDZjN2daMGZwQ0w4Z2JBQmJ4VVRlN1VyS1I5cksyNWRHTy1CTm04TmEzSmpIdUtZM3NldTU?oc=5","date":"2026-01-24","type":"pipeline","source":"Barron's","summary":"Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. - Barron's","headline":"Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNVVlQMElFcnlldlQ4X3R3Mko5Sy16V3ZJanZUcVpoZzgtLTczbFhpT1B4Z251bkJtM1pvMVY2N0I0bXlObHNDRjJOejQyM3FhQzZ1TVhEby1rSENPSzZCQ0JMRUhWN2MzS2xULXZYUlIxU1BqOXNIZDQ5UkZFbk8tUXkwOUN1V0xRaHMtcEhXMTVXN0lxVnhhRXhFSG4wYnZpZURZQWwzQWhOWU1qbUoxazN2VXpmY2xOSjRjWlF2dEE3X25w?oc=5","date":"2026-01-15","type":"deal","source":"Reuters","summary":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - Reuters","headline":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQemI0NnB4YzZNMXNpeEc0UTN6eXF1blJneFB0OHBBZnhBbFJrU2tQUENBbGpNRzJKZzZSd0FjRXNMUXpiWUlEZ08yOFpocmlBTGxaMFVfTEo0dlBBd2NhdkFFTDhuNG16RUg3c3NtMHF6WTNROTEyV0xwWmhZTTZjRjlDeFhPRnJneDhuMG1jZUotS1F3X21WZ2ZDVnRrZXV5SF9NSEJqVlNMQmNsdjN5ZXlOdHpuQ2ZC?oc=5","date":"2026-01-15","type":"deal","source":"PR Newswire","summary":"Boston Scientific announces agreement to acquire Penumbra, Inc. - PR Newswire","headline":"Boston Scientific announces agreement to acquire Penumbra, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQY2h6OGpub0hCM2d0Q3FFeHJ3cjE5LWFGVzdIazdDUmNxVF8tTDJ3bWN5N0QyLVRIMTZrdlNwX25DaXkxYi1pcm84OUkwem93V244bVd4Wm9KemMteGNUa0ZkRU9mLXdfYV9pTE1iQlJ3ZVU5SUR0VHN6Y2VFT2JNSXQ4eE40Z0phZk9yV2Y5TllWN2ZIMGh6aEl3aS1qdlpkaFpUaFFxS3LSAa4BQVVfeXFMUG9kbTNZOVVBcWViTS1PUEZIUTZXWFRVNXdjZ0NBNlNCWW1ld3NaVWNtVllxMmlKVlpMalBoTUdqczFhWFdlNTd3VmJCTk9EcmVqSlIwRjV1LUtTcHRXMnhRZHhzcWdkTVVBbkxCd3NIVHVqVTBHV0xUQXdOY3R1d20zWnJEVEJqZG00N21VTXVjNG9FMGJHUl8xb3VZNjJJWTNnbEt6b29ITmJSM3Z3?oc=5","date":"2026-01-15","type":"deal","source":"CNBC","summary":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - CNBC","headline":"Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE93bGNvMGpGOUJHMVZiUlhJU1M3QU5QZ1BJUExRUTZ2c2p0V0hyRFVDQjJEMFhvVlN6NjlfVGliS19IQjE0a3RRTGJReVAzUmVJVDJvcjhqYWZQUWhaNFZVOElpNWlET3NjbERfRnNLekRYOHZt?oc=5","date":"2025-12-10","type":"earnings","source":"Finviz","summary":"3 Profitable Stocks That Fall Short - Finviz","headline":"3 Profitable Stocks That Fall Short","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPd2ZJZktpbEJ1SHVoZFN4WjZFMld3MXVId0hUWFdBWVhkcmQ0QWZVSE5CaVZfd0tpWUJWLUZiQ3B1NUhwaS1iU3ZId3YxcGlSS212SzdlZFp3MVVMWkxqdXQzRUhSdWV3U2NMUkZOOTRmUHg4Skl2bjV4QzJxRjVVTEVqZnpLaUlWTHNnU1lIbjJxZzhYXzAzdGRuaS15NGhXc19Ia205XzVqcWxHLXlXX3pmMm56RDl5TlFicFlIbDFwaFY5YW9yS3lpNDM?oc=5","date":"2025-11-25","type":"earnings","source":"Finviz","summary":"Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 In Review: Penumbra (NYSE:PEN) Vs Peers - Finviz","headline":"Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 In Review: Penumbra (NYSE:PEN) Vs Peers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNZEs4ZWRLV1QwOFFuNDRWMkp6U0JJWlA4b2l5eUMtYTNBeHRrT0Rpd0U2cktZZUFUVTFJd3ZiRmhHMzZrU1gyVFRiSWJDWlBaME9EZW0tRjZjVUkzTUxSbFY3VXFHeXJJczh4OF9yVDI5UWdnVTBsTUhtcXZaZ3FQY1RLUklyOXgtWTk2RlpZczFObDhLdVBvS2YwM0x5V2JwY2ZldWE1WjRtcnRaN3RGYk9yWDNmcVdVQnlFdlh3S3pHWHNPNklRZjF4cTIzZw?oc=5","date":"2025-07-09","type":"deal","source":"Reuters","summary":"Major deals involving U.S. drugmakers and biotechs over the past decade - Reuters","headline":"Major deals involving U.S. drugmakers and biotechs over the past decade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNQ3VkNW5XMnZCTC1BanFDY0d1NTVBdFdCVjJ2bm5kNVZ6QklrRTNVRDVvQUZwU1lQakhudXExX2RkbHh6ZFNOQU1lZWJqTFpidEZPS1VZZ2duNWZGVWcyV19lNndRVkZORmI3S19JRDJHeUNMZlhtT1BoaTFvQTRKQmc0a3gybl9WWV8zU3R4YVJHVWRKVWZGTWxobF91Zw?oc=5","date":"2025-06-26","type":"pipeline","source":"Seeking Alpha","summary":"Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner - Seeking Alpha","headline":"Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE5aOEJDY21oWlBHUFB0THBrVktjWm5rLUY2YVdoa256UzhJODkxMG5EMlNiRERHdXhxOWN1ekF1b3JkdDBXZXBMR25IRTFKYlE?oc=5","date":"2024-02-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Medtronic","Boston Scientific","Stryker"],"therapeuticFocus":["Neurovascular","Neurosurgery"],"financials":{"source":"sec_edgar+yahoo","revenue":1403665000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1403665000,"period":"2025-12-31"},{"value":1194615000,"period":"2024-12-31"},{"value":1194615000,"period":"2024-12-31"},{"value":1058522000,"period":"2023-12-31"},{"value":1058522000,"period":"2023-12-31"}],"grossProfit":942437000,"grossProfitHistory":[{"period":"2025-12-31","value":942437000},{"period":"2024-12-31","value":754995000},{"period":"2023-12-31","value":682643000},{"period":"2022-12-31","value":535207000}],"rdSpend":36165000,"rdSpendHistory":[{"period":"2025-12-31","value":89766000},{"period":"2024-12-31","value":94783000},{"period":"2023-12-31","value":84423000},{"period":"2022-12-31","value":79407000}],"sgaSpend":663422000,"operatingIncome":189249000,"operatingIncomeHistory":[{"period":"2025-12-31","value":189249000},{"period":"2024-12-31","value":86224000},{"period":"2023-12-31","value":91766000},{"period":"2022-12-31","value":6082000}],"netIncome":177687000,"netIncomeHistory":[{"period":"2025-12-31","value":177687000},{"period":"2024-12-31","value":14012000},{"period":"2023-12-31","value":90954000},{"period":"2022-12-31","value":-2002000}],"eps":4.52,"epsHistory":[{"period":"2025-12-31","value":4.52},{"period":"2024-12-31","value":0.36},{"period":"2023-12-31","value":2.32},{"period":"2022-12-31","value":-0.05}],"cash":186897000,"cashHistory":[{"period":"2025-12-31","value":186897000},{"period":"2024-12-31","value":324404000},{"period":"2023-12-31","value":167486000},{"period":"2022-12-31","value":69858000}],"totalAssets":1826519000,"totalLiabilities":398916000,"totalDebt":219699000,"equity":1427603000,"operatingCashflow":238663000,"operatingCashflowHistory":[{"period":"2025-12-31","value":238663000},{"period":"2024-12-31","value":168481000},{"period":"2023-12-31","value":97333000},{"period":"2022-12-31","value":-55661000}],"capex":-63729000,"capexHistory":[{"period":"2025-12-31","value":-63729000},{"period":"2024-12-31","value":-21182000},{"period":"2023-12-31","value":-15213000},{"period":"2022-12-31","value":-19298000}],"freeCashflow":174934000,"dividendsPaid":null,"buybacks":0,"employees":4700,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":192795000,"ebit":42005000,"ebitda":46579000,"period":"2026-03-31","revenue":374758000,"epsBasic":0.83,"netIncome":32584000,"rdExpense":22382000,"epsDiluted":0.82,"grossProfit":253411000,"operatingIncome":38234000},{"sga":181101000,"ebit":63965000,"ebitda":68426000,"period":"2025-12-31","revenue":385385000,"epsBasic":1.21,"netIncome":47343000,"rdExpense":21794000,"epsDiluted":1.2,"grossProfit":262128000,"operatingIncome":59233000},{"sga":168901000,"ebit":52663000,"ebitda":55151000,"period":"2025-09-30","revenue":354685000,"epsBasic":1.17,"netIncome":45851000,"rdExpense":22677000,"epsDiluted":1.17,"grossProfit":240416000,"operatingIncome":48838000},{"sga":159964000,"ebit":45629000,"ebitda":51136000,"period":"2025-06-30","revenue":339455000,"epsBasic":1.15,"netIncome":45270000,"rdExpense":23218000,"epsDiluted":1.15,"grossProfit":224010000,"operatingIncome":40828000},{"sga":153456000,"ebit":44180000,"ebitda":49195000,"period":"2025-03-31","revenue":324140000,"epsBasic":1.02,"netIncome":39223000,"rdExpense":22077000,"epsDiluted":1,"grossProfit":215883000,"operatingIncome":40350000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":322.2,"previousClose":322.59,"fiftyTwoWeekHigh":362.41,"fiftyTwoWeekLow":221.26,"fiftyTwoWeekRange":"221.26 - 362.41","fiftyDayAverage":331.21,"twoHundredDayAverage":298.9,"beta":0.73,"enterpriseValue":12288439296,"forwardPE":51.2,"priceToBook":8.85,"priceToSales":8.71,"enterpriseToRevenue":8.45,"enterpriseToEbitda":60.25,"pegRatio":0.74,"ebitda":203963008,"ebitdaMargin":14,"freeCashflow":141799872,"operatingCashflow":276664000,"totalDebt":216175008,"debtToEquity":14.7,"currentRatio":6.02,"returnOnAssets":6.7,"returnOnEquity":12.7,"analystRating":"2.6 - Hold","recommendationKey":"hold","numberOfAnalysts":14,"targetMeanPrice":363.36,"targetHighPrice":374,"targetLowPrice":326,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.9,"institutionHeldPercent":93.6,"sharesOutstanding":39331425,"floatShares":38136536,"sharesShort":1896966,"shortRatio":3.22,"shortPercentOfFloat":4.8,"epsTrailing":4.35,"epsForward":6.3,"revenuePerShare":37.2,"bookValue":36.39,"officers":[{"age":63,"name":"Mr. Adam  Elsesser J.D.","title":"Co-Founder, Chairman & CEO"},{"age":40,"name":"Ms. Shruthi  Narayan","title":"President"},{"age":63,"name":"Dr. Arani  Bose M.D.","title":"Co-Founder & Director"},{"age":53,"name":"Ms. Maggie S. Yuen","title":"Chief Financial Officer"},{"age":45,"name":"Mr. Lambert  Shiu","title":"Chief Accounting Officer"},{"age":53,"name":"Ms. Johanna  Roberts J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":null,"name":"Mr. Ben  Sorci","title":"Executive Vice President of Operations"},{"age":null,"name":"Mr. Pankaj  Tiwari","title":"Executive VP & Chief Information Officer"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.penumbrainc.com","phone":"510 748 3200"}}